Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU 11C02

Title
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Principal Investigator
Jeffrey Raizer
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU 11C02
Purpose
The purpose of this study is to determine the effectiveness and safety of combining multiple types of treatments for patients who have recurrent high grade brain tumors.
Overview
Participants in this study have a high grade glioma which has been treated in the past and has recurred. Typically, patients receive one or more of several types of treatments, including radiation therapy, chemotherapy such as temozolomide, and other treatments that circulate through the body, like bevacizumab. All of these treatments have been used in past for patients with glioma, and we think that using all three of these treatments together is safe and may be more effective than using them separately.
Eligibility
Some of the eligibility criteria include:
  • Participants must be at least 18 years of age.
  • Participants must be diagnosed with glioblastoma or anaplastic glioma.
  • Participants must have been previously treated with radiation therapy and temozolomide or radiation therapy, temozolomide and bevacizumab.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
This study will use all three of the above treatments together and may be more effective than using them separately. Participants will receive radiation therapy every weekday for 5 weeks (25 treatments). During radiation therapy, participants will take temozolomide by mouth every day and will receive bevacizumab into a vein in the arm every two weeks. After the radiation is complete participants will continue with additional cycles of the bevacizumab and temozolomide (1 cycle = 8 weeks). Participants will take temozolomide by mouth daily for the first 6 weeks of each cycle, and will receive bevacizumab infusions every two weeks.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 25-Oct-14 08:50 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.